100.00% -8.28

Cybin Inc (CYBN)

概要ニュース株価時系列ディスカッション予測

Cybin Inc (CYBN) 最新ニュース

Cybin Inc (CYBN)

Cybin Inc (CYBN) 最新ニュース

Robert Langer, who helped found Moderna, joins Helus Pharma board - Stock Titan

How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative - simplywall.st

[SCHEDULE 13G/A] CYBIN INC. Amended Passive Investment Disclosure - Stock Titan

symbol__ Stock Quote Price and Forecast - CNN

Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade) (NASDAQ:HELP) - Seeking Alpha

Trump's Executive Order May Boost Psychedelic Stocks. Here Are 7 to Buy in 2026 - U.S. News Money

Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN

Helus Pharma CEO Michael Cola steps down at board’s request By Investing.com - Investing.com India

Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN

Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways - TipRanks

Helus Pharma (Nasdaq: CYBN) aligns late-stage NSA pipeline with U.S. psychedelic policy push - Stock Titan

Helus Pharma (CYBN) CEO steps down as co-founder Eric So becomes interim chief - Stock Titan

Psychedelic Stocks Surge After Executive Order, Focus on Compass Pathways (CMPS) - GuruFocus

Helus Pharma CEO Michael Cola steps down at board’s request - Investing.com

Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions - The Manila Times

White House psychedelics push intersects with Helus Phase 3 depression drug - Stock Titan

Helus Pharma Announces CEO Changes Effective April 20, 2026 - marketscreener.com

Cybin Inc. Common Stock (HELP) - Minichart

Cybin Insider Ups Holding By 105% During Year - Yahoo Finance

HELP Options Chain — NASDAQ:HELP - TradingView

Millennium Management LLC Acquires Additional Shares in Helus Ph - GuruFocus

Psychedelic Stocks Tracker - Psychedelic Alpha

Helus Pharma (Nasdaq: HELP; CYBN) taps Dr. Ken Kramer to lead medical - Stock Titan

Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs - Investing News Network

Helus Pharma Taps Neuroscience Veteran Ken Kramer to Lead Medical Affairs - TipRanks

Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN

HELP Initiated Coverage by TD Cowen -- Price Target Set at $8 - GuruFocus

Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Aug PostEarnings: What hedge funds are buying Cybin Inc2026 Historical Comparison & Daily Chart Pattern Signals - baoquankhu1.vn

Cybin (NASDAQ:HELP) Now Covered by TD Cowen - MarketBeat

Top Cybin (HELP) Competitors 2026 - MarketBeat

HELP: Cybin Inc.Brokerage Recommendations Chart - Zacks Investment Research

Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - ADVFN

Millennium Group (CYBN) reports 2.51M shares, 5.0% stake - Stock Titan

Rate Cut: Will Cybin Inc stock recover after earningsRisk Management & Technical Pattern Based Signals - baoquankhu1.vn

Can Cybin (HELP) Stock Beat Estimates | Price at $5.33, Up 1.52%Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai

Aug Decliners: Does Cybin Inc stock have upside surprise potential2026 Short Interest & Weekly Breakout Watchlists - baoquankhu1.vn

Total non-current assets of Cybin, Inc. – NEO:HELP - TradingView — Track All Markets

Cybin Inc (NASDAQ:HELP) - intelligentinvestor.com.au

HELP Should I Buy - Intellectia AI

HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill

Trend Recap: Is Cybin Inc on track to beat earningsTrade Entry Report & Long-Term Safe Investment Ideas - baoquankhu1.vn

Guidance Update: Can Cybin Inc be the next market leader2026 Analyst Calls & Accurate Entry and Exit Point Alerts - baoquankhu1.vn

CYBNに似た銘柄